Hamilton Robert G, Kickler Thomas S
Division of Allergy and Clinical Immunology and Hematology, Departments of Medicine and Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA.
Transfusion. 2007 Apr;47(4):723-8. doi: 10.1111/j.1537-2995.2007.01176.x.
Bovine hemoglobin (Hb)-based oxygen carrier (HbOC-201; Hb glutamer-250, Hemopure, Biopure Corp.) is a blood replacement and augmentation drug that increases oxygen-carrying capacity of circulating blood in patients with anemia and acute blood loss. The objective of this study was to assess the biologic significance (cross-reactivity, hemolysis) of humoral immune responses in humans receiving repetitive HbOC-201 administrations.
Serum samples containing immunoglobulin G (IgG) anti-HbOC-201 (n = 146) or no antibody (n = 16) were collected from subjects receiving HbOC-201 in clinical studies. IgG anti-HbOC-201 levels were quantified and the extent of cross-reactivity to human hemoglobin (HuHb) was assessed in direct-binding and competitive-inhibition immunoassays. Serum samples containing the highest levels of IgG anti-HbOC-201 were studied in a complement-mediated hemolysis assay for their ability to lyse human red cells (RBCs).
The IgG anti-HbOC-201 levels in the antibody-positive serum samples ranged from 0.7 to 86.8 mug per mL. Of the 146 IgG anti-HbOC-201-positive serum samples, 88.4 percent contained IgG antibodies whose binding to solid-phase HbOC-201 was competitively inhibited by incubation with soluble HuHb (11.6% [<20% inhibition]; 63% [20%-80% inhibition]; and 25.4% [>81% inhibition]). Direct-binding analysis to solid-phase HuHb confirmed that 74 percent contained IgG antibodies reactive with HuHb. Dichotomous competitive inhibition and direct-binding IgG anti-HuHb data correlated significantly (r(2) = 0.77, p < 0.001). Serum samples with the highest levels of IgG anti-HuHb, as identified from clinical studies, did not lyse human RBCs in the presence of exogenous complement or induce the direct sensitization of RBCs with human IgG or complement.
These analyses indicate that HbOC-201 administration elicits IgG antibodies in humans that react with bovine and HuHb, but do not cause hemolysis in vitro.
基于牛血红蛋白(Hb)的氧载体(HbOC - 201;血红蛋白谷氨酰胺 - 250,Hemopure,Biopure公司)是一种血液替代和补充药物,可增加贫血和急性失血患者循环血液的携氧能力。本研究的目的是评估接受重复注射HbOC - 201的人体中体液免疫反应的生物学意义(交叉反应性、溶血)。
在临床研究中,从接受HbOC - 201的受试者中收集含有免疫球蛋白G(IgG)抗HbOC - 201(n = 146)或不含抗体(n = 16)的血清样本。对IgG抗HbOC - 201水平进行定量,并在直接结合和竞争抑制免疫测定中评估与人类血红蛋白(HuHb)的交叉反应程度。在补体介导的溶血试验中研究含有最高水平IgG抗HbOC - 201的血清样本裂解人类红细胞(RBC)的能力。
抗体阳性血清样本中的IgG抗HbOC - 201水平范围为每毫升0.7至86.8微克。在146份IgG抗HbOC - 201阳性血清样本中,88.4%含有IgG抗体,其与固相HbOC - 201的结合通过与可溶性HuHb孵育而受到竞争性抑制(11.6% [<20%抑制];63% [20% - 80%抑制];25.4% [>81%抑制])。对固相HuHb的直接结合分析证实,74%含有与HuHb反应的IgG抗体。二分法竞争抑制和直接结合IgG抗HuHb数据显著相关(r² = 0.77,p < 0.001)。从临床研究中鉴定出的具有最高水平IgG抗HuHb的血清样本,在外源性补体存在下不会裂解人类RBC,也不会用人IgG或补体诱导RBC的直接致敏。
这些分析表明,注射HbOC - 201会在人体中引发与牛和HuHb反应的IgG抗体,但在体外不会引起溶血。